{"id":"W3164179066","doi":"10.1136/rmdopen-2021-001595","title":"Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure","year":2021,"lang":"en","type":"article","venue":"RMD Open","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Genentech; Bausch Health; Celltrion; Astellas Pharma; Sanofi; Kyowa Hakko Kirin; Coherus Biosciences; Sun Pharma; Dermira; F. Hoffmann-La Roche; Ironwood Pharmaceuticals, Incorporated; Regeneron Pharmaceuticals; Baxalta; Boston Pharmaceuticals; LEO Pharma; Gilead Sciences; GlaxoSmithKline; Allergan; AstraZeneca; Seres Therapeutics; Amgen; Meiji Seika Pharma; Pfizer; Celgene; Galderma; Celltrion Healthcare; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Tofacitinib; Medicine; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis; Psoriasis; Internal medicine; Adverse effect; Clinical trial; Arthritis; Incidence (geometry); Dermatology; Disease","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02688413,0.0008926649,0.003216257,0.001355026,0.0005820573,0.001497368,0.0006629457,0.0008683744,0.003594072],"category_scores_gemma":[0.03315881,0.0004418232,0.005559355,0.002965499,0.0007100407,0.001291933,0.001327378,0.001601733,0.0003572517],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001101117,"about_ca_system_score_gemma":0.00121265,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004061537,"about_ca_topic_score_gemma":0.001057065,"domain_scores_codex":[0.9545718,0.02323529,0.01144381,0.004453315,0.005405603,0.0008902097],"domain_scores_gemma":[0.9438879,0.024328,0.0276341,0.001631355,0.001522086,0.0009965308],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1598603,0.0006911853,0.6466104,0.01996523,0.04444931,0.0009546811,0.0005355322,0.004173703,0.00352611,0.0006778877,0.004661563,0.1138941],"study_design_scores_gemma":[0.01782743,0.02521909,0.9074013,0.002234995,0.02051396,0.003681635,0.000235099,0.001424683,0.002646371,0.001064438,0.01761869,0.0001323172],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8514128,0.1210338,0.003427437,0.0006934857,0.0002941311,0.004426125,0.01216811,0.0001180134,0.006426182],"genre_scores_gemma":[0.9824731,0.007112125,0.001419557,0.000388831,0.0002417152,0.003163632,0.004301675,0.00002449086,0.0008749348],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02688413,"threshold_uncertainty_score":0.1421786,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06746329276828503,"score_gpt":0.3602680577919297,"score_spread":0.2928047650236446,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}